Ysios Capital achieves Certification under the Diversity VC Standard

by Ysios Capital

3 years ago
Ysios Capital, Future VC, Diversity VC, Certification

Ysios Capital is the first specialized venture capital firm in life sciences globally and the first Spanish firm to achieve the Diversity VC Standard, an assessment and certification process that sets...

Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ

by Ysios Capital

3 years ago
Ysios Capital, CVRx, Inc, LAVA Therapeutics

Ysios Capital, a leading Spanish biotechnology venture capital firm, today announced that its portfolio company CVRx Inc. has priced its initial public offering (IPO) and is trading on the Nasdaq Glob...

Ysios Capital closes its third fund at €216 million ($260 million)

by Ysios Capital

3 years ago
Ysios Capital, Ysios Biofund III

Ysios Capital, Spain’s largest and leading European venture capital firm specialised in the biotechnology sector, announces today that it has closed its third fund, Ysios BioFund III (YBF III) at...

Cytoki Pharma raises $45 million Series A financing

by Ysios Capital

3 years ago
Ysios Capital, +ND Capital, Seventure Partners, Lundbeckfonden Emerge, Cytoki Pharma

Cytoki Pharma ApS, a private biotech company incorporated in Copenhagen, Denmark, today announced a $45 million series A financing led by existing investor Lundbeckfonden Emerge (Denmark) together ...

Adcendo raises EUR 51 Million in Series A Financing led by Novo Holdings and Ysios Capital to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

by Ysios Capital

3 years ago
Adcendo, Gilde Healthcare, Ysios Capital, RA Capital Management, Novo Seeds

Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The ...

Synendos Therapeutics Expands Series A to CHF 24 million with new investment. Ysios Capital joins other investors

by Ysios Capital

3 years ago
Ysios Capital, Eurostars Funding Programme, SERIs, Synendos Therapeutics, Central Nervous System

Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, today annou...

Vivet Therapeutics, supported by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals

by Ysios Capital

3 years ago
Mirum Pharmaceuticals, Vivet Therapeutics, Columbus Venture Partners, Ysios Capital

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Viv...

LAVA Therapeutics, supported by Ysios Capital, Announces Pricing of Initial Public Offering

by Ysios Capital

3 years ago
LAVA Therapeutics, Ysios Capital

LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of i...

Aura Biosciences, supported by Ysios Capital, Announces Oversubscribed $80 Million Financing

by Ysios Capital

3 years ago
Aura Biosciences, Ysios Capital, Life Sciences

Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an oversubsc...

Splice Bio, backed by Ysios Capital, Asabys Partners and Caixa Capital Risc, appoints Jean-Philippe Combal as Chairman of the Board of Directors

by Ysios Capital

3 years ago
Splice Bio, Ysios Capital, Asabys Partners, Caixa Capital Risc

Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed JeanPhilippe Combal as Chairman of its Board of Director...

CorWave Raises €35 Million in Series C Funding for Its Breakthrough Heart Pump; EIC Fund Joins as New Investor

by Ysios Capital

3 years ago
implantable heart pump, CorWave, heart failure, medtech company, investment, EIC Fund

CorWave raises 35 million euros to fund the next stages of its development, with the ambition to become a world-class medtech company serving heart failure patients. The capital increase is subscribed...

Ysios Capital portfolio company Galecto, Inc. prices IPO on Nasdaq

by Ysios Capital

4 years ago
Galecto, Ysios Capital, Ysios BioFund II Innvierte, cancer, fibrosis

Ysios Capital, a leading Spanish biotechnology venture capital firm, today announced that its portfolio company Galecto Inc. has priced its initial public offering (IPO) and is trading on the Nasdaq G...